Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.05
AGN's Cash to Debt is ranked lower than
95% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. AGN: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
AGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.47 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.57
AGN's Equity to Asset is ranked lower than
58% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AGN: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
AGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.61 Max: 0.93
Current: 0.57
0.25
0.93
F-Score: 6
Z-Score: 1.12
M-Score: -2.47
WACC vs ROIC
7.66%
-1.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -12.34
AGN's Operating margin (%) is ranked lower than
80% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. AGN: -12.34 )
Ranked among companies with meaningful Operating margin (%) only.
AGN' s Operating margin (%) Range Over the Past 10 Years
Min: -21.33  Med: 6.99 Max: 14.12
Current: -12.34
-21.33
14.12
Net-margin (%) 26.25
AGN's Net-margin (%) is ranked higher than
93% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. AGN: 26.25 )
Ranked among companies with meaningful Net-margin (%) only.
AGN' s Net-margin (%) Range Over the Past 10 Years
Min: -22.48  Med: 5.41 Max: 25.98
Current: 26.25
-22.48
25.98
ROE (%) 5.87
AGN's ROE (%) is ranked lower than
54% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. AGN: 5.87 )
Ranked among companies with meaningful ROE (%) only.
AGN' s ROE (%) Range Over the Past 10 Years
Min: -23.54  Med: 6.44 Max: 12.05
Current: 5.87
-23.54
12.05
ROA (%) 3.38
AGN's ROA (%) is ranked lower than
52% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. AGN: 3.38 )
Ranked among companies with meaningful ROA (%) only.
AGN' s ROA (%) Range Over the Past 10 Years
Min: -13.02  Med: 3.54 Max: 6.67
Current: 3.38
-13.02
6.67
ROC (Joel Greenblatt) (%) -40.04
AGN's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. AGN: -40.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -112.05  Med: 20.55 Max: 39.38
Current: -40.04
-112.05
39.38
Revenue Growth (3Y)(%) -3.80
AGN's Revenue Growth (3Y)(%) is ranked lower than
76% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. AGN: -3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.8  Med: 17.50 Max: 39.8
Current: -3.8
-3.8
39.8
EBITDA Growth (3Y)(%) 0.80
AGN's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. AGN: 0.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 3.60 Max: 41.1
Current: 0.8
-3.7
41.1
» AGN's 10-Y Financials

Financials (Next Earnings Date: 2016-08-08)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AGN Guru Trades in Q3 2015

Wallace Weitz 187,607 sh (New)
Kyle Bass 17,813 sh (New)
First Pacific Advisors 30,580 sh (New)
Jim Simons 53,969 sh (New)
Ruane Cunniff 1,103,395 sh (New)
Paul Singer 663,000 sh (New)
Jeremy Grantham 819,684 sh (+79558.31%)
Diamond Hill Capital 66,793 sh (+1265.91%)
George Soros 774,566 sh (+386.12%)
Signature Select Canadian Fund 35,400 sh (+233.96%)
Alan Fournier 652,100 sh (+196.41%)
Paul Tudor Jones 11,317 sh (+90.62%)
Julian Robertson 59,700 sh (+34.16%)
Jana Partners 1,886,931 sh (+16.59%)
Steve Mandel 2,607,655 sh (+13.48%)
John Griffin 1,630,842 sh (+11.24%)
Daniel Loeb 3,669,000 sh (+11.18%)
First Eagle Investment 1,671,156 sh (+8.07%)
Andreas Halvorsen 7,202,384 sh (+5.85%)
Private Capital 169,620 sh (+2.23%)
Vanguard Health Care Fund 9,190,927 sh (+1.69%)
John Paulson 7,182,000 sh (+0.11%)
David Carlson 340,000 sh (unchged)
First Eagle Investment 335 sh (unchged)
Bernard Horn 20,689 sh (unchged)
Chris Davis 2,100 sh (unchged)
Louis Moore Bacon Sold Out
John Burbank Sold Out
Howard Marks Sold Out
John Keeley Sold Out
Pioneer Investments 692,942 sh (-2.59%)
Scott Black 38,015 sh (-2.80%)
Ken Fisher 3,185 sh (-11.03%)
Leon Cooperman 811,635 sh (-12.01%)
RS Investment Management 358,388 sh (-13.66%)
Mario Gabelli 31,862 sh (-14.55%)
Larry Robbins 1,523,609 sh (-23.16%)
Dodge & Cox 1,100 sh (-31.29%)
Lee Ainslie 580,418 sh (-60.23%)
» More
Q4 2015

AGN Guru Trades in Q4 2015

Ron Baron 11,752 sh (New)
David Einhorn 410,000 sh (New)
Louis Moore Bacon 6,816 sh (New)
Eric Mindich 948,569 sh (New)
Steven Cohen 73,200 sh (New)
David Tepper 150,000 sh (New)
Joel Greenblatt 42,240 sh (New)
John Hussman 5,000 sh (New)
Paul Tudor Jones 50,857 sh (+349.39%)
Jim Simons 206,701 sh (+283.00%)
Paul Singer 2,020,500 sh (+204.75%)
Daniel Loeb 5,400,000 sh (+47.18%)
John Griffin 2,000,000 sh (+22.64%)
Vanguard Health Care Fund 10,962,347 sh (+19.27%)
Alan Fournier 765,800 sh (+17.44%)
Lee Ainslie 679,930 sh (+17.14%)
Mario Gabelli 33,473 sh (+5.06%)
Wallace Weitz 196,170 sh (+4.56%)
Ken Fisher 3,306 sh (+3.80%)
Paul Tudor Jones 20,000 sh (unchged)
Bernard Horn 20,689 sh (unchged)
David Carlson 340,000 sh (unchged)
Paul Singer 770,000 sh (unchged)
Samuel Isaly 343,025 sh (unchged)
Julian Robertson Sold Out
Chris Davis Sold Out
Dodge & Cox Sold Out
Kyle Bass Sold Out
Steve Mandel Sold Out
Larry Robbins Sold Out
RS Investment Management 352,778 sh (-1.57%)
Ruane Cunniff 1,085,870 sh (-1.59%)
Private Capital 166,017 sh (-2.12%)
Leon Cooperman 781,780 sh (-3.68%)
Pioneer Investments 632,600 sh (-8.71%)
Diamond Hill Capital 57,154 sh (-14.43%)
Andreas Halvorsen 5,978,075 sh (-17.00%)
First Pacific Advisors 24,100 sh (-21.19%)
John Paulson 5,532,600 sh (-22.97%)
Jana Partners 1,164,663 sh (-38.28%)
George Soros 365,390 sh (-52.83%)
First Eagle Investment 669,995 sh (-59.91%)
Jeremy Grantham 281,993 sh (-65.60%)
Scott Black 7,453 sh (-80.39%)
» More
Q1 2016

AGN Guru Trades in Q1 2016

Steve Mandel 1,789,239 sh (New)
Jerome Dodson 40,000 sh (New)
Seth Klarman 1,721,587 sh (New)
Ron Baron 27,278 sh (+132.11%)
Lee Ainslie 1,410,362 sh (+107.43%)
Eric Mindich 1,875,073 sh (+97.67%)
Paul Tudor Jones 100,489 sh (+97.59%)
David Tepper 279,109 sh (+86.07%)
Wallace Weitz 304,722 sh (+55.34%)
Paul Singer 2,497,051 sh (+23.59%)
Mario Gabelli 39,798 sh (+18.90%)
Pioneer Investments 700,680 sh (+10.76%)
David Carlson 370,000 sh (+8.82%)
David Einhorn 437,200 sh (+6.63%)
Diamond Hill Capital 60,724 sh (+6.25%)
Vanguard Health Care Fund 11,187,547 sh (+2.05%)
Paul Tudor Jones 140,000 sh (unchged)
Paul Singer 770,000 sh (unchged)
Alan Fournier 500,000 sh (unchged)
John Paulson 214,700 sh (unchged)
John Hussman 5,000 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
First Pacific Advisors Sold Out
John Paulson 5,418,300 sh (-2.07%)
Ken Fisher 3,225 sh (-2.45%)
Private Capital 161,728 sh (-2.58%)
Signature Select Canadian Fund 34,300 sh (-3.11%)
Ruane Cunniff 1,025,555 sh (-5.55%)
RS Investment Management 330,590 sh (-6.29%)
Daniel Loeb 5,000,000 sh (-7.41%)
Bernard Horn 17,389 sh (-15.95%)
Andreas Halvorsen 4,881,957 sh (-18.34%)
John Griffin 1,502,700 sh (-24.87%)
Leon Cooperman 561,265 sh (-28.21%)
Jeremy Grantham 188,267 sh (-33.24%)
Scott Black 4,905 sh (-34.19%)
Alan Fournier 500,000 sh (-34.71%)
First Eagle Investment 371,770 sh (-44.51%)
George Soros 143,277 sh (-60.79%)
Jana Partners 446,893 sh (-61.63%)
Joel Greenblatt 14,367 sh (-65.99%)
Samuel Isaly 341,025 sh (-0.58%)
» More
Q2 2016

AGN Guru Trades in Q2 2016

Jerome Dodson 102,000 sh (+155.00%)
Spiros Segalas 1,380,144 sh (+6.09%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA916.766.005 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:TEVA, OTCPK:TKPYY, NYSE:ZTS, NAS:MYL, OTCPK:ESALY, OTCPK:SGIOF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:APNHY, OTCPK:MTZPY, NYSE:RDY, OTCPK:TAISF, OTCPK:HLUYY, OTCPK:HKMPY, NYSE:VRX, NYSE:MNK, OTCPK:MDABY, NYSE:TARO, OTCPK:SFOSF, NAS:OPK » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.

Ratios

vs
industry
vs
history
P/E(ttm) 23.91
AGN's P/E(ttm) is ranked higher than
60% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.41 vs. AGN: 23.91 )
Ranked among companies with meaningful P/E(ttm) only.
AGN' s P/E(ttm) Range Over the Past 10 Years
Min: 10.94  Med: 26.31 Max: 366.63
Current: 23.91
10.94
366.63
Forward P/E 18.15
AGN's Forward P/E is ranked lower than
56% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. AGN: 18.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 45.41
AGN's Price/Owner Earnings (ttm) is ranked lower than
61% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. AGN: 45.41 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.13  Med: 19.41 Max: 1279.04
Current: 45.41
8.13
1279.04
P/B 1.38
AGN's P/B is ranked higher than
79% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. AGN: 1.38 )
Ranked among companies with meaningful P/B only.
AGN' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 1.75 Max: 5.9
Current: 1.38
1.03
5.9
P/S 5.58
AGN's P/S is ranked lower than
69% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. AGN: 5.58 )
Ranked among companies with meaningful P/S only.
AGN' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 5.58
0.99
17.57
PFCF 21.19
AGN's PFCF is ranked higher than
52% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. AGN: 21.19 )
Ranked among companies with meaningful PFCF only.
AGN' s PFCF Range Over the Past 10 Years
Min: 6.62  Med: 14.87 Max: 36.71
Current: 21.19
6.62
36.71
POCF 18.98
AGN's POCF is ranked lower than
55% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. AGN: 18.98 )
Ranked among companies with meaningful POCF only.
AGN' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 12.22 Max: 31.19
Current: 18.98
5.97
31.19
EV-to-EBITDA 32.35
AGN's EV-to-EBITDA is ranked lower than
74% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. AGN: 32.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 10.00 Max: 386.1
Current: 32.35
-224.1
386.1
Shiller P/E 1078.28
AGN's Shiller P/E is ranked lower than
99% of the 151 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 50.39 vs. AGN: 1078.28 )
Ranked among companies with meaningful Shiller P/E only.
AGN' s Shiller P/E Range Over the Past 10 Years
Min: 14.77  Med: 50.65 Max: 1507.14
Current: 1078.28
14.77
1507.14
Current Ratio 0.99
AGN's Current Ratio is ranked lower than
89% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. AGN: 0.99 )
Ranked among companies with meaningful Current Ratio only.
AGN' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.89 Max: 9.8
Current: 0.99
0.99
9.8
Quick Ratio 0.89
AGN's Quick Ratio is ranked lower than
80% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. AGN: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.98 Max: 8.82
Current: 0.89
0.78
8.82
Days Inventory 127.22
AGN's Days Inventory is ranked lower than
58% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. AGN: 127.22 )
Ranked among companies with meaningful Days Inventory only.
AGN' s Days Inventory Range Over the Past 10 Years
Min: 75.66  Med: 119.26 Max: 133.19
Current: 127.22
75.66
133.19
Days Sales Outstanding 54.28
AGN's Days Sales Outstanding is ranked higher than
68% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. AGN: 54.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.08  Med: 58.63 Max: 92.81
Current: 54.28
31.08
92.81
Days Payable 31.02
AGN's Days Payable is ranked lower than
85% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.26 vs. AGN: 31.02 )
Ranked among companies with meaningful Days Payable only.
AGN' s Days Payable Range Over the Past 10 Years
Min: 18.72  Med: 59.11 Max: 107.57
Current: 31.02
18.72
107.57

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.34
AGN's Price/Projected FCF is ranked higher than
80% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. AGN: 1.34 )
Ranked among companies with meaningful Price/Projected FCF only.
AGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.17 Max: 3.29
Current: 1.34
0.61
3.29
Price/Median PS Value 3.07
AGN's Price/Median PS Value is ranked lower than
90% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. AGN: 3.07 )
Ranked among companies with meaningful Price/Median PS Value only.
AGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.36 Max: 8.52
Current: 3.07
0.67
8.52
Earnings Yield (Greenblatt) (%) -1.56
AGN's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. AGN: -1.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.6  Med: 6.10 Max: 12.3
Current: -1.56
-1.6
12.3
Forward Rate of Return (Yacktman) (%) 1.91
AGN's Forward Rate of Return (Yacktman) (%) is ranked lower than
61% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. AGN: 1.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.4  Med: 7.50 Max: 16.1
Current: 1.91
-2.4
16.1

More Statistics

Revenue (TTM) (Mil) $17,837
EPS (TTM) $ 10.76
Beta1.08
Short Percentage of Float1.44%
52-Week Range $195.50 - 340.34
Shares Outstanding (Mil)395.56

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 16,798 18,248 19,874
EPS ($) 14.25 17.56 20.64
EPS w/o NRI ($) 14.25 17.56 20.64
EPS Growth Rate
(3Y to 5Y Estimate)
10.42%
Dividends Per Share ($)
» More Articles for NYSE:AGN

Headlines

Articles On GuruFocus.com
Jerome Dodson's Best Investments Jul 27 2016 
Daniel Loeb's Third Point 2nd-Quarter 2016 Investor Letter Jul 27 2016 
Jerome Dodson Comments on Allergan Jul 26 2016 
Jerome Dodson's Parnassus Fund 2nd Quarter Commentary Jul 26 2016 
Weitz Funds Comments on Allergan Jul 20 2016 
Ruane Cunniff Comments on Allergan Jul 13 2016 
Sequoia Fund Addresses Valeant, New Buys, Board Changes in 2nd Quarter Letter Jul 13 2016 
3 of Paul Singer's Top 5 Deals in 1st Quarter Involve Technology Stocks Jun 26 2016 
Steve Mandel Exits Position in Williams Companies in 1st Quarter Jun 24 2016 
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 

More From Other Websites
Teva Pharmaceutical Finance Issued the Most High-Grade Bonds Jul 28 2016
Teva Said Close to Closing $40.5 Billion Allergan Deal Jul 28 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Teva expect to close $40.5B Allergan generic deal next week Jul 27 2016
Teva expect to close $40.5B Allergan generic deal next week Jul 27 2016
[$$] Teva, Allergan Get FTC Approval for Generics Purchase Jul 27 2016
FTC approves Teva's $40.5B deal for Allergan's generics business Jul 27 2016
ALLERGAN PLC Files SEC form 8-K, Other Events Jul 27 2016
Teva purchase of Allergan generics business approved with conditions Jul 27 2016
Third Point's 1st-half returns boosted by energy credit investments Jul 26 2016
Jerome Dodson Comments on Allergan Jul 26 2016
Jerome Dodson's Parnassus Fund 2nd Quarter Commentary Jul 26 2016
Street Talk: Mondelez & more Jul 25 2016
Allergan Gets Positive Opinion For Its Truberzi For Irritable Bowel Syndrome With Diarrhoea... Jul 25 2016
Credit Suisse says Allergan's drug pipeline is 'underappreciated' Jul 25 2016
Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel... Jul 25 2016
Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel... Jul 25 2016
Jim Cramer -- I Agree With the Analysts on Gap, Allergan Jul 25 2016
Why Traders Are Watching Tesla, SolarCity, Allergan & Other Stocks Today Jul 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)